389 related articles for article (PubMed ID: 29180398)
1. Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model.
Garcia-Santos D; Hamdi A; Saxova Z; Fillebeen C; Pantopoulos K; Horvathova M; Ponka P
Blood; 2018 Jan; 131(2):236-246. PubMed ID: 29180398
[TBL] [Abstract][Full Text] [Related]
2. RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.
Schmidt PJ; Liu K; Visner G; Fitzgerald K; Fishman S; Racie T; Hettinger JL; Butler JS; Fleming MD
Am J Hematol; 2018 Jun; 93(6):745-750. PubMed ID: 29498084
[TBL] [Abstract][Full Text] [Related]
3. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.
Kautz L; Jung G; Du X; Gabayan V; Chapman J; Nasoff M; Nemeth E; Ganz T
Blood; 2015 Oct; 126(17):2031-7. PubMed ID: 26276665
[TBL] [Abstract][Full Text] [Related]
4. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S
J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112
[TBL] [Abstract][Full Text] [Related]
5. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.
Schmidt PJ; Toudjarska I; Sendamarai AK; Racie T; Milstein S; Bettencourt BR; Hettinger J; Bumcrot D; Fleming MD
Blood; 2013 Feb; 121(7):1200-8. PubMed ID: 23223430
[TBL] [Abstract][Full Text] [Related]
6. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
Matte A; Federti E; Kung C; Kosinski PA; Narayanaswamy R; Russo R; Federico G; Carlomagno F; Desbats MA; Salviati L; Leboeuf C; Valenti MT; Turrini F; Janin A; Yu S; Beneduce E; Ronseaux S; Iatcenko I; Dang L; Ganz T; Jung CL; Iolascon A; Brugnara C; De Franceschi L
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822774
[TBL] [Abstract][Full Text] [Related]
7. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
[TBL] [Abstract][Full Text] [Related]
8. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia.
Olivera J; Zhang V; Nemeth E; Ganz T
Blood Adv; 2023 Jul; 7(14):3339-3349. PubMed ID: 36995275
[TBL] [Abstract][Full Text] [Related]
9. Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of β-thalassemia.
Matte A; Federti E; Winter M; Koerner A; Harmeier A; Mazer N; Tomka T; Di Paolo ML; De Falco L; Andolfo I; Beneduce E; Iolascon A; Macias-Garcia A; Chen JJ; Janin A; Lebouef C; Turrini F; Brugnara C; De Franceschi L
JCI Insight; 2019 Nov; 4(22):. PubMed ID: 31593554
[TBL] [Abstract][Full Text] [Related]
10. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.
Gardenghi S; Marongiu MF; Ramos P; Guy E; Breda L; Chadburn A; Liu Y; Amariglio N; Rechavi G; Rachmilewitz EA; Breuer W; Cabantchik ZI; Wrighting DM; Andrews NC; de Sousa M; Giardina PJ; Grady RW; Rivella S
Blood; 2007 Jun; 109(11):5027-35. PubMed ID: 17299088
[TBL] [Abstract][Full Text] [Related]
11. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196
[TBL] [Abstract][Full Text] [Related]
12. Exogenous iron increases hemoglobin in beta-thalassemic mice.
Ginzburg YZ; Rybicki AC; Suzuka SM; Hall CB; Breuer W; Cabantchik ZI; Bouhassira EE; Fabry ME; Nagel RL
Exp Hematol; 2009 Feb; 37(2):172-83. PubMed ID: 19059700
[TBL] [Abstract][Full Text] [Related]
13. Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
Schmidt PJ; Fitzgerald K; Butler JS; Fleming MD
Am J Hematol; 2021 Feb; 96(2):251-257. PubMed ID: 33180328
[TBL] [Abstract][Full Text] [Related]
14. The Interplay Between Peroxiredoxin-2 and Nuclear Factor-Erythroid 2 Is Important in Limiting Oxidative Mediated Dysfunction in β-Thalassemic Erythropoiesis.
Matte A; De Falco L; Iolascon A; Mohandas N; An X; Siciliano A; Leboeuf C; Janin A; Bruno M; Choi SY; Kim DW; De Franceschi L
Antioxid Redox Signal; 2015 Dec; 23(16):1284-97. PubMed ID: 26058667
[TBL] [Abstract][Full Text] [Related]
15. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.
Nai A; Pagani A; Mandelli G; Lidonnici MR; Silvestri L; Ferrari G; Camaschella C
Blood; 2012 May; 119(21):5021-9. PubMed ID: 22490684
[TBL] [Abstract][Full Text] [Related]
16. Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle.
Bohl D; Bosch A; Cardona A; Salvetti A; Heard JM
Blood; 2000 May; 95(9):2793-8. PubMed ID: 10779423
[TBL] [Abstract][Full Text] [Related]
17. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
19. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V
Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842
[TBL] [Abstract][Full Text] [Related]
20. Identification of erythroferrone as an erythroid regulator of iron metabolism.
Kautz L; Jung G; Valore EV; Rivella S; Nemeth E; Ganz T
Nat Genet; 2014 Jul; 46(7):678-84. PubMed ID: 24880340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
